Heart shield: diabetes drug may protect breast cancer patients from chemo side effects
NCT ID NCT06491680
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tests if dapagliflozin, a drug used for diabetes, can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. About 40 adults with breast cancer who are scheduled for anthracycline treatment will take dapagliflozin or a placebo. Researchers will measure heart function and blood markers to see if the drug offers protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Al demerdash hospital at oncology departement
RECRUITINGCairo, Cairo Governorate, 202, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.